Accepted for/Published in: JMIR Research Protocols
Date Submitted: Sep 15, 2020
Date Accepted: Nov 1, 2020
Date Submitted to PubMed: Nov 6, 2020
ReumaCoV Brasil Registry: a Brazilian cohort of Patients with Immuno-mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2
ABSTRACT
Background:
Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk of infections, including significant morbidity and high mortality. Considering the potential for unfavorable outcomes of SARS-CoV-2 infection in patients with IMRD, several questions were released regarding the impact of COVID-19 in the beginning of the pandemic.
Objective:
To evaluate prospectively patients with IMRD and a confirmed COVID-19 diagnosis, according to the Brazilian Ministry of Health criteria.
Methods:
Prospective, observational cohort, with a comparison group, with a follow-up time of 6 months. The primary outcomes will be the IMRD disease activity changes after COVID-19, at four time points: (1) At baseline; (2) Within 4-6 weeks after infection by SARS-CoV-2; (3) 3 months after the second assessment (±15 days); (4) 6 months after (±15 days). The secondary outcomes will be the progression rate to moderate-severe forms of COVID-19, need for intensive care unit admission and mechanical ventilation, death and therapeutic changes related to the IMRD. Two outcomes are of particular interest considering the COVID-19 in IMRD patients, namely pulmonary and the thromboembolic events, and they will be monitored with more attention and details (clinical, lab, function tests and imaging).
Results:
Recruitment opened in May, 2020, with 1000 participants recruited and 43 sites opened as of september 2020. Patient recruitment will be closed on October, 2020, with follow-up occurring until April, 2021. Data analysis is scheduled to start after all inclusion data have been collected, with an aim to publish a peer-reviewed article in October, 2020.
Conclusions:
We believe this study will provide many clinically relevant data on the general impact of COVID-19 on IMRD patients. Clinical Trial: This protocol was approved by the Brazilian Committee of Ethics in Human Research (CONEP) in April 5th, 2020 (CAAE 30186820.2.1001.8807; Number: 3.933.204) and registered on the Brazilian Registry of Clinical Trials – REBEC (RBR-33YTQC) in June, 1st 2020.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.